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Background: Over one million men are diagnosed with prostate cancer each year
worldwide, with a wide range of research programs requiring access to patient tissue
samples for development of improved diagnoses and treatments. Random sampling of
prostate tissue is sufficient for certain research studies, however there is a growing
research need to target areas of aggressive tumor as fresh tissue. Here we set out to
develop a new pathway “PEOPLE: PatiEnt prOstate samPLes for rEsearch” to collect
high quality fresh tissue for research use, using magnetic resonance imaging (MRI) to
target areas of tumor and benign tissue.
Methods: Prostate tissue was sampled following robotic radical prostatectomy, using
MRI data to target areas of benign and tumor tissue. Initially, 25 cases were sampled
using MRI information from clinical notes. A further 59 cases were sampled using an
optimized method that included specific MRI measurements of tumor location along
with additional exclusion criteria. All cases were reviewed in batches with detailed
clinical and histopathological data recorded. For one subset of samples DNA was
extracted and underwent quality control. Ex vivo culture was carried out using the
gelatin sponge method for an additional subset.
Results: tumor was successfully fully or partially targeted in 64% of the initial cohort
and 70% of the optimized cohort. DNA of high quality and concentration was isolated
from 39 tumor samples, and ex vivo culture was successfully carried out in three cases
with tissue morphology, proliferation and apoptosis remaining comparable before and
after 72 h culture.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in
any medium, provided the original work is properly cited and is not used for commercial purposes.
© 2019 The Authors. The Prostate Published by Wiley Periodicals, Inc.
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Conclusion:Here we report initial data from the PEOPLE pathway; using a method for
targeting areas of tumor within prostate samples using MRI. This method operates
alongside the standard clinical pathway and minimizes additional input from surgical,
radiological and pathological teams, while preserving surgical margins and diagnostic
tissue.
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1 | INTRODUCTION
Prostate cancer is the second most common cancer in men worldwide,
with an estimated 1.1 million men having been diagnosed with the
disease in 2012.1 Current prostate cancer research programmes are
often focused on betterways to diagnose and treat aggressive prostate
cancer, while sparingmenwithmore indolent cancers fromundergoing
unnecessary procedures and treatments. In order to best address these
priorities, there is an increasing research need for high quality prostate
tissue which represents the index lesion. With a wide range of
emerging technologies being adopted in prostate cancer research,
there is also a growing need for fresh tissue that can either be used
immediately or banked for larger studies, for example in ex vivo
culture, ex vivo MRI for assessment of new treatments and/or
biomarkers or for large cohort genomic studies such as the
International Cancer Genome Consortium (ICGC) and The Cancer
Genome Atlas (TCGA). For studies requiring live cells researchers must
be able to identify areas of tumor and benign tissue for experimental
use immediately upon tissue collection, rather than fix or freeze tissue
and wait for results from histological analysis.
Numerous methods have been published for sampling radical
prostatectomy specimens for research without impeding on the
diagnostic pathway. Key considerations across each published method
include the minimization of ischemia time, control of temperature
during transport and processing, preservation of surgical margins for
pathological examination and careful recording of positions of samples
within the prostate. One early method involved slicing the prostate in
half immediately in theater, taking research biopsies for freezing and
then suturing the prostate back together for fixation.2 Anothermethod
involved slicing the whole prostate fresh in 4mm slices, and storing
one whole slice for research in RNAlater, while the rest were fixed and
stored as formalin fixed paraffin embedded (FFPE) blocks for
pathological assessment.3 Sooriakumaran et al4 published a method
in 2011 which involved slicing and taking mapped punch biopsies for
immediate storage in RNAlater in theatre, followed by fixation of
remaining sections in histology cassettes. The team later confirmed
consistently high RNA integrity independent of ischemia time.5 In
order to generate larger frozen specimens suitable for inclusion in the
ICGC, another group quartered and flash froze alternate slices of the
prostate for biobanking. This resulted in the generation of large
amounts research specimens, but also large proportions of surgical
margins not being available for routine histological processing,
although the banked samples could be accessed later by pathology
if required for further diagnostic tests.6
Our previous prostate sampling publication7 built upon these
published methods to generate large quantities of high quality biopsy
punches for research from radical prostatectomy specimens without
affecting surgical margins. The method included pinning the prostate
capsule to a cork board following sampling in order to ensure surgical
margins did not become warped during fixation. Samples were taken
randomly across a full transverse slice and stored without knowledge
of tumor content. The method was highly successful for the ICGC
study, where tumor content could be assessed at a later date.
However, the ability to be reasonably confident of tumor content in
real time is essential for many research applications requiring fresh
tissue. The ability to use tissue immediately with high confidence of
tumor content opens up a wide range of new technologies for prostate
cancer research, in particular new imaging techniques and ex vivo
culture.
With numerous Magnetic Resonance Imaging (MRI) clinical trials
and studies reporting the efficacy of MRI in diagnosing clinically
significant prostate cancer, there is an increasing trend towards using
MRI prior to transperineal template biopsy to diagnose patients with
suspected prostate cancer.8–11 This represents an ideal opportunity to
better target research samples, by incorporating a review of MRI data
into the sampling procedure.
Here we set out to use MRI to build upon previously published
prostate sampling methods, enabling researchers to target specific
areas of tumor and benign tissue within radical prostatectomy
specimens, and use tissue either immediately fresh, or frozen or fixed
as applicable to the specific study requirements.
2 | MATERIALS AND METHODS
2.1 | Tissue samples
Patients were recruited and consented under Genomics England's
100,000 Genome Project ethics at University College Hospital
between March 2016 and July 2017, with a subset of patients also
consented under UCL/UCLH Biobank ethics (REC 15/YH/0311). A
summary of the clinical characteristics of these patients is included in
Table 1.
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2.2 | Tissue sampling from radical prostatectomy
specimens
Prostates were collected from theatres immediately upon removal
from the patient during robotic radical prostatectomy at UCLH and
transported under UN3373 guidelines to the UCLH Pathology
Department. If suitable staff were not available to sample the prostate
immediately, the specimen was stored at 4°C for up to 24 h in
accordance with Genomics England guidelines. The prostate was
weighed and inked, and a 5mm transverse slice was removed using the
parallel blade device as previously published.7 tumor and benign areas
were identified and 1-2 samples of each removed as per the
requirements of each study, using 3mm or 6mm biopsy punches.
tumor regions typically felt slightly denser and occasionally looked
paler and this was taken into account when selecting regions to
sample.
Remaining tissuewas pinned to cork, fixed in 10%neutral buffered
formalin and processed as per local protocols. This process was initially
carried out by pathologists, and later two trained postdoctoral
researchers signed off as competent to carry out the procedure,
under supervision of a pathologist.
2.3 | Tumor targeting using MRI
All patients received a multiparametric (mp) prostateMRI prior to their
robotic radical prostatectomy, either at UCLH or at their referring
hospital (Table 2). Two methods were used to target tumor samples
using MRI data (Table 3).
2.3.1 | Initial method
All patients undergoing robotic radical prostatectomy at UCLH are
discussed at a surgical planning meeting, where a surgical planning
sheet was filled out with details of tumor location according to both
biopsy andMRI data (Figure 1A). This sheetwas uploaded centrally and
accessed when planning the tissue sampling to take a transverse slice
towards the apex, mid gland or base as indicated, and then take a 3mm
or 6mm tissue punch from the region identified as containing a
suspicious lesion.
2.3.2 | Optimized method
Following review of the surgical planning sheet, MRI images were
visualized using IMPAX software (version 6.5, AGFA-Gevaert,Mortsel,
Belgium) and T2 weighted axial, T2 weighted coronal, diffusion
weighted imaging (DWI) and apparent diffusion coefficient (ADC)
images used to identify the index lesion, defined as the largest tumor
focus within the prostate. A measurement was then taken from the
base of the prostate to the target lesion in mm within the software,
using the image where the tumor was most visible − typically the T2
weighted axial image (Figure 1B). Once trained by a board certified
radiologist (EJ), a postdoctoral researcher could carry out this
procedure in less than five minutes per patient. During the sampling
procedure, a transverse slice was removed at the position identified
previously using theMRI image,measured from the base of the prostate
TABLE 1 Patient characteristics
Patient Characteristics N = 84
Age at surgery (years) 62.1 ± 6.77
Tumor volume (mL) 3.57 ± 2.14
Prostate volume (cc) 39.18 ± 14.59
PSA (ng/dL) 10.86 ± 8.07
Gleason Grade
3 + 3: 4 (4.76%)
3 + 4: 50 (59.52%)
4 + 3: 22 (26.19%)
4 + 4: 7 (8.33%)













Research specimens were collected from 84 prostate cancer patients who
underwent robot assisted radical prostatectomy at UCLH between
March 2016 and July 2017. Key clinical characteristics are noted here
with additional information in Supplementary data file S1.
TABLE 2 MRI location
MRI Location Patients n (%)
Royal Free Hospital (North West London) 14 (16.66%)
St Bartholomew's Hospital (Central London) 12 (14.29%)
Barnet General Hospital (North London) 11 (13.1%)
Princess Alexandra Hospital (Harlow, Essex) 10 (11.9%)
University College London Hospitals (Central
London)
10 (11.9%)
King George Hospital (East London) 9 (10.7%)
North Middlesex University Hospital (North
London)
5 (5.95%)
Whipps Cross University Hospital (East London) 3 (3.57%)
Other 7 (8.33%)
Althoughallpatients underwent surgeryatUCLH,MRIwascarriedoutacross
13 hospitals with the majority of patients referred to UCLH post MRI. The
number of patients from each hospital is given with the percentage of the
overall cohort in brackets. Hospitals where less than three patients
underwent MRI were grouped to avoid potential identification of patients,
and include Homerton University Hospital, Whittington Hospital, Enfield
Alliance Hospital, Queen's Hospital and St. Margaret's Hospital.
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by a ruler in mm (Figure 1C). After the first 6 cases were sampled, an
additional stepwascarriedout to identify anyshrinkage that couldaffect
the accuracy of this method. Here, length of the prostatewasmeasured
from base to apex on the coronal T2MRI image, and compared with the
length of the prostate measured by ruler immediately before slicing.
Basedupon the amount of shrinkage observed an adhoc correctionwas
applied before identifying the position to slice. Exclusion criteria were
applied to omit patients who had undergone prior therapy, had no
distinct lesion by MRI (ie, only diffuse changes) and patients who had
lesions smaller than 5mm visible on MRI.
2.4 | Tissue storage
Tissue cores were stored depending on the individual study. At least
one core from each patient was embedded in optimized cutting
temperature compound (OCT), snap frozen in liquid nitrogen
immediately and then stored at −80°C. For subsets of cases, additional
benign or tumor tissue was either snap frozen dry in cryovials in liquid
nitrogen, fixed immediately in 10% neutral buffered formalin and
stored as FFPE blocks, or transported inwarmmedia for ex vivo culture
(ex vivo culture was not carried out where prostates had been stored
overnight before sampling).
2.5 | Assessment of tumor content
All 84 samples assessed for tumor content had been stored frozen in
OCT. Samples were sectioned at 5 µm thickness using sterile
technique on the cryostat, then stained immediately with haematox-
ylin and eosin (H &E) as per 100 000 Genomes Project standard
operating procedures. Slides were assessed by an experienced
consultant uropathologist and tumor content was reported as 0, 5,
10, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100%.
2.6 | Tissue data review
All specimens were reviewed in batches, by a multidisciplinary team
including at least one consultant uropathologist alongwith a pathology
registrar, postdoctoral researchers and technicians. All anonymized
data is included in Supplementary Data File S1 and includes whether
the specimen was refrigerated prior to sampling, number of samples
taken, whether the initial or optimized tumor targeting method was
used, which member of the pathology team supervised cut up, which
area(s) were sampled, which level the sample was taken, distance to
tumor on the same level if tumor was missed, whether the tumor could
have been hit if samples were taken on the next/previous level in the
same position, the total number of levels, the number of levels the
tumor was present in, the level where tumor(s) reached maximum
dimension, the maximum tumor dimension, the number of tumors in
the specimen, the most affected area of the prostate by MRI versus
biopsy, prostate volume and weight, tumor volume, Gleason grade,
pathological tumor staging, MRI (Likert), the hospital the MRI was
carried out in, tumor volume, patient age, PSA, base-apex length (MRI),
base-apex length (ruler), base-apex shrinkage (%), cellularity (very low
[<700 total cells], low [4000 cells], medium [4000-10 000 total cells],
high [>10 000 total cells], very high [>50 000 total cells]), number of
10 μm sections submitted for DNA extraction, which sample used for
frozen sections (if more than one was available), DNA concentration
and 260:280 ratio.
2.7 | DNA isolation
DNA was isolated from 20 to 40 frozen tissue sections per sample
(10 µm) from 39 cases, taken adjacent to sections used for tumor
content assessment, as per 100 000 Genomes Project standard
operating procedures. The Maxwell 16 LEV Blood DNA Kit
(AS1290; Promega) was used to extract DNA. Prior to extraction
samples were homogenized by the addition of 300 µL lysis buffer and
30 µL Proteinase K (Promega) to each sample, followed by incubation
at 56°C for at 30min. Samples were then transferred to Maxwell 16
LEV Cartridges for extraction, according to the manufacturer's
protocol. DNA was eluted in 70 µL Elution Buffer (Promega).
Concentration was assessed using the Qubit dsDNA HS Assay Kit
with the Qubit Fluorometer (ThermoFisher) and 260:280 ratio
TABLE 3 Tumor Targeting Methods
Method Description Exclusion criteria
Initial
method
Surgical planning sheet reviewed (biopsy and MRI notes and sketches from radiologists, pathologists and
surgeons)




Surgical planning sheet reviewed (biopsy and MRI notes and sketches from radiologists, pathologists and
surgeons)
Prior therapy
MRI review: Identification of index lesion based on surgical planning sheet, measurement of prostate
length (base − apex, mm) and distance from base to desired transverse slice (mm).
No observable lesion, or
only diffuse changes by
MRI
Prostate measured, correction factor applied if shrinkage had occurred and transverse slice taken at
measured position from base, then biopsy punches taken based on surgical planning sheet sketches and
visibility or palpability of tumor where possible.
Lesion smaller than
5mm
The first 25 patients recruited under PEOPLEwere part of an initial cohort, where a basic tumor targeting approachwas used and outlined here. The following
59 specimens were sampled using an optimized approach with more specific MRI targeting, also outlined here.
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FIGURE 1 Tumor Targeting Methods. Following review of the surgical planning sheet, the index lesion is identified in MRI images. The
position of the optimal transverse slice is identified and a measurement is taken from the base to this position and from the base to apex
using a coronal T2 weighted image (A). The position of the tumor is noted, here in an axial T2 weighted image (B). Following radical
prostatectomy, the full surgical margins are inked right side blue, left side black according to local protocol, then the prostate is measured
from base to apex and a correction factor is applied if the prostate has shrunk in comparison with the MRI image. The position of the desired
5mm transverse slice is identified (C). Following slicing, the area of expected tumor is confirmed if possible visually and/or palpably, with
some tumors appearing paler and denser than benign tissue. 6 mm biopsy punches are used to remove samples from indicated tumor and
benign areas (D). One tumor sample is submitted to Genomics England for DNA extraction, quality control, whole genome sequencing and
data analysis as part of the 100 000 Genomes Project (E). Matched tumor and benign samples are submitted for use in ex vivo gelatin sponge
culture, or other ethically approved research projects in a subset of cases (F). [Color figure can be viewed at wileyonlinelibrary.com]
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assessed using the Nanodrop Fluorometer (ThermoFisher) according
to manufacturer's instructions.
2.8 | Ex vivo culture
Ex vivo culture was carried out using the gelatin sponge method.12
Sponges were placed in a 24 well plate with 200 µL/well Roswell Park
Memorial Institute media (RPMI) supplemented with 10% fetal bovine
serum 2-3 h prior to tissue collection to allow the sponges to draw up
the media in a 37 °C, 5% CO2 incubator. Fresh 3mm or 6mm cores
were divided as appropriate using a sterile scalpel and placed on the
damp sponges, then incubated for 72 hr. Both uncultured control
samples and samples that were cultured for 72 h were fixed in 10%
neutral buffered formalin and stored as FFPE blocks. 4 µm sections
from the FFPE blocks were stained with H&E, or assessed for Ki67 by
immunohistochemistry performed on the BondMax autostainer (Leica)
(Dakom7240, 1:100 dilution, F. Dabe 1min haematoxylin, ER2 30min)
and cleaved caspase 3 (Cell Signalling 9664) 1:200 dilution, F. Dabe
1min haematoxylin, ER2 20min.
3 | RESULTS
Eighty-four prostates were sliced and sampled for various research
projects under the PEOPLE pathway, with tumors targeted using the
initial method for 25 prostates and optimized method for 59 prostates
(Figure 1). Patient characteristics are reported in Table 1. All surgery
was carried out in UCLH and MRIs were carried out in 13 different
hospitals across Greater London and Essex (Table 2).
After the first 25 cases a detailed case review was carried out and
seven cases were identified where the tumor was missed. All could
potentially have been accurately targeted had the transverse slice
been taken more towards the base or apex of the prostate
(Supplementary Data File S1). This resulted in a change to the
optimized method where measurements from the MRI image were
used to target the transverse slice and tumor.
In order to account for shrinkage that can occur following surgery,
46 prostates were measured using a ruler from base to apex, and
compared with MRI measurements of the same distance. The majority
of prostates did shrink, with a mean shrinkage of 5.71 ± 10.57% and a
trend towards larger prostates shrinking more and smaller prostates
shrinking less (P = 0.0002) (Figure 2A). Some prostates increased in
size, possibly due to growth between the time the MRI image was
taken and surgery.
All tumor samples were assessed for tumor content by a
consultant uro-pathologist, using frozen H&E sections. Forty
percent of samples taken using the initial method and 60% of
samples taken using the optimized method had tumor content of at
least 40%, and therefore could be submitted without macro-
dissection for sequencing under the 100,000 Genomes Project
(Figure 2B). Samples that had between 5 and 30% tumor content
were considered ‘partial hits’ and could potentially be used for
sequencing following macrodissection. The sum of hits and partial
hits for the initial method was 64% and for the optimized method
was 70% (Figure 2C).
As well as the risk of missing the tumor when taking the
transverse slice, there was also a risk of missing the tumor within the
slice when taking punch biopsies. It appeared that accuracy in hitting
tumor within the slice improved slightly over time, although this
trend was not statistically significant (P = 0.344), based on measure-
ments taken from the sampled area to the nearest tumor within that
slice (Figure 2D).
The crucial aspect of the PEOPLE method is tumor targeting,
and in order to maximize the efficacy of this we used both MRI and
biopsy data to assess tumor location within the prostate for
sampling. Where biopsy and MRI data did not agree, both indicated
areas were targeted if possible, and if not, MRI data was used alone.
During retrospective histopathological assessment, the consultant
pathologist noted which area of the radical prostatectomy slides
was most affected, for example, left posterior. This was subse-
quently compared to the planning protocol. In cases where the
surgical planning sheet estimated by both biopsy and MRI that the
tumor was in this position (left posterior), it was considered that
both biopsy and MRI estimated tumor position well. If only one or
neither of these indicated accurately the most affected area of the
prostate, this was noted (Supplementary Data File S1, Table 2).
Following assessment of all samples it was found that both MRI and
biopsy data only correctly estimated the same location of highest
Gleason tumor in 35% of cases, with MRI outperforming biopsy in
46% of cases and biopsy outperforming MRI in 16% of cases
(Figure 2E). There were three cases where neither the MRI nor the
biopsy correctly estimated the location of the tumor. In all three
cases the tumor was present in the transverse slice, but the tissue
sample was not taken from the area of the slice where the tumor
was present. Two of these cases were reported Likert 2 by MRI (low
likelihood of tumor presence) and one was reported Likert 3
(equivocal likelihood of tumor presence). These three prostates
were also low in weight (mean 36 g vs 48 g cohort mean) and tumor
volume (mean 2.6 mL vs 4.4 mL cohort mean) (highlighted orange in
Supplementary Data File S1).
Hit rate was found not to significantly differ by tumor volume
(SupplementaryFigureS1A),prostatevolume (SupplementaryFigureS1B)
or ISUP grade (Supplementary Figure S1C). MRI (likert) did not correlate
well with Gleason grade (Supplementary Figure S1D) or tumor volume
(Supplementary Figure S1E), although this cohort is underpowered to
consider the accuracy of MRI in this regard. The initial and optimized
method did not differ by ISUP grade (Supplementary Figure S1F).
Thirty-nine samples were submitted for sequencing under the
100 000 Genomes Project. DNA was eluted in a final volume of 70 µL,
and was analyzed using spectrophotometry. All had 260:280 ratios of
1.8-2.0, with an average concentration of 41.7 ± 18.92 ng/µL.
Cellularity of each sample was noted by a pathologist as very low
(<700 total cells), low (4000 cells), medium (4000-10 000 total cells),
high (>10 000 total cells), very high (>50 000 total cells), and there was
no significant difference in DNA concentration between each
cellularity grouping (Figure 2F).
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FIGURE 2 Key data from case review. Prostate length was measured in mm in MRI images and using a ruler post-surgery and an ad hoc
correction for shrinkage applied each time prior to slicing (A). tumor content was assessed by a uropathologist based on H&E staining of frozen
sections of tumor targeted samples. Mean tumor content was 29.6% for the initial targeting method and 44.8% for the optimized targeting
method. All samples above the threshold of 40% tumor content were deemed eligible for next generation sequencing as per 100 000 Genome
Project Guidelines. A two tailed Mann-Whitney was performed and the difference between the two cohorts was deemed non-significant (B).
Samples where 5-40% tumor was identified were noted as “partial hits” and could be macrodissected in order to be submitted for next
generation sequencing. C, Distance from punch taken to nearest tumor on the same slice was measured and plotted sequentially in the order of
patients sampled, with linear regression not identifying a significantly non-zero slope (D). The location of most significant tumor was recorded
based on MRI, biopsy and radical prostatectomy data. It was recorded whether MRI, biopsy, both or neither best indicated the location of most
significant disease post radical prostatectomy (E). DNA was isolated from 39 cases for next generation sequencing under the 100 000 Genomes
Project. Almost all cases yielded concentrations over 20 ng/µL and those that did not were repeated with more sections and submitted for
sequencing. Data is noted for the first DNA isolation of each case, with non-significant q values from a one way ANOVA and Tukey test (F)
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Three samples were cultured ex vivo using the gelatin sponge
method.12 Control samples were stored as FFPE blocks at the
time of sampling and after 72 h culture at 37 °C, and 4 µm sections
were stained with H&E, the proliferation marker Ki67 and
apoptosis marker cleaved caspase 3. Minimal-no differences
in morphology, proliferation or apoptosis were noted between
cultured and uncultured samples in cases one and two, while some
loss of tissue integrity was noted for patient three, which could be
optimized in future using different media or shorter culture.
(Figure 3).
FIGURE 3 Ex vivo culture Tissue from three cases was cultured ex vivo for 72 h using the gelatin sponge method. Samples were stored as FFPE
blocks after 72 h (untreated tissue), with matched uncultured samples also stored FFPE (uncultured tissue). Sections were then stained with H&E
(morphology), Ki67 (proliferation) and cleaved caspase-3 (apoptosis) to assess whether tissue from PEOPLE is of sufficient quality for culture. [Color
figure can be viewed at wileyonlinelibrary.com]
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4 | DISCUSSION
Anumber ofmethods have beendescribed for the collectionof prostate
cancer tissue for research following radical prostatectomy. A 2017
review on these existing methods highlighted the importance of
reducing numbers of samples taken from surgical specimens, and
suggested the use of imaging and biopsy data to better target lesions for
sampling.13Here,weaddress thisbyusingMRI to target specific areasof
tissue that can then be used immediately for research, vastly increasing
the range of experimental techniques that can be exploited, while still
integrating well within the clinical pathway.
Previous prostate tissue collection methods have sampled areas of
thegland randomly, orbypalpatingor viewing the tumoras slightlymore
dense or pale. These methods are sufficient for certain downstream
techniques, but are unlikely to be reliable for routine collection of high
tumor content samples based upon our data that demonstrates that the
average tumor only occupies 11% of the overall prostate volume, and is
oftennotdiscernibleby eyeor touch from the surrounding benign tissue
(Figure 1D).MRI has been heralded as amajor step forward for prostate
cancer diagnosis, with findings frommultiple clinical trials advocating its
routine use.8–11 With this gain in popularity comes an opportunity for
researchers to exploit MRI data to improve fresh tissue collection, here
allowing us to successfully target tumor in 70% of samples (Figure 2C).
We have incorporated MRI into the sampling method in order to
improve tumor targeting andwhilst UCLH is aworld leader inMRI,most
patients in our cohort had imaging at one of twelve other hospitals
across the Greater London / Essex area before coming for surgery at
UCLH. The varying quality of theMRI data did not impact on our ability
to target tumors and we predict that this method can be successful
wherever MRI is carried out prior to surgery (Table 2).
The major disadvantage of previous methods was the lack of
confidence in the pathology of the sampled tissue that limited its
utility and often required extensive sampling and/or pathologist time
to identify samples with high tumor content.2,3 The key benefit of
incorporating MRI guided tumor targeting into the sample collection
pathway is the increased freedom this provides to carry out a much
wider range of downstream experiments. As with previous method-
ologies, samples can be stored in RNAlater for expression analysis,
fixed and stored as FFPE for immunohistochemistry, or frozen for
genomics studies, all with greater confidence in the content of each
sample prior to histological assessment.4,5 Here, tumor samples were
frozen and DNA of consistently high purity and quantity for
sequencing was isolated for the 100,000 Genomes Project
(Figure 2F). Crucially, this targeting method also allows for the
development of new methodologies which require fresh matched
tumor and benign tissue. For example, ex vivo MRI or other imaging
techniques can be carried out on fresh tissue quickly following
surgery, allowing researchers to more effectively study density and
other physical properties than with fixed or frozen tissue.14 The
method we describe here allows techniques such as ex vivo culture,
more widely used in breast cancer research, to be carried out to test
new drugs or biomarkers.12,15–17 We cultured tumor and benign
tissue for 72 h using the gelatin sponge method and were able to
show that untreated tissue post culture had minimal degradation in
morphology, proliferation and apoptosis as uncultured tissue
(Figure 3). As prostate cancer research progresses, we predict
more methods will emerge which require high quality fresh tumor
tissue. In order to do these experiments using previously described
tissue collection methods, researchers would need to over-collect
samples and use a substantial excess to ensure presence of tumor.
This is unfeasible in terms of both cost, time and an unethical use of
human tissue that could be better utilized in other studies.
Although this method contains additional steps compared with
previously published methods, including our own, we succeeded in
reducing the time burden on clinical staff using a protocol that
dovetailed with the standard clinical pathway and could be performed
by trained postdoctoral researchers and technicians.7 This included
measurement of MRI data, meaning the only radiology department
input required was for training at the beginning of the study. This
reduced the burden on the overall clinical system and allowed for
flexible sample collection for research projects when required by the
researchers. Additionally, surgical margins and diagnostic tissue are
preserved as before.7
Although this new method does allow for a wider range of
downstream applications and minimizes any additional burden on the
pathologist, it does not significantly improve upon previously
published tumor hit rates overall. This is due to the reduced tissue
sampling carried out here, where 1-2 indicated tumor and matched
benign punch biopsies are taken for immediate experimentation,
leading to a tumor hit rate of 70%, rather than the previous methods of
taking many samples, often from several prostate slices and assessing
tumor content of each sample later, which has led to tumor hit rates
from69 to 100%.13 It remains useful to discuss the 30%of caseswhere
tumor was missed here, with a view to further refinement of the
pathway for implementation in new centers. Interestingly, in the cases
where tumor was missed, there was no discernible difference in ISUP
grade, MRI (Likert), tumor volume, tumor location or prostate volume,
and as such we have not added further restrictions to our recruitment
criteria based on these parameters. There were three cases where
neither the biopsy nor theMRI indicated the location of the tumorwell.
These cases had lower tumor volume, prostate weight and MRI Likert
score, none of which were out of the range of this cohort, but perhaps
these criteria together, and taken in the context of differing biopsy &
MRI results could be used to identify potential patients to avoid
recruiting in future iterations of this method.
High quality prostate cancer research relies on access to high
quality human tissue for experimentation. Here we have built upon
existing tissue sampling methodologies to introduce the PEOPLE
pathway, providing high quality MRI targeted fresh tissue for a wide
range of research.
5 | CONCLUSIONS
We report our initial data from the PEOPLE pathway, an improvement
to our previously published prostate slicing method, where we utilize
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MRI data to target and collect high quality tumor and benign prostate
tissue that can be used for a wide variety of research applications such
as next generation sequencing or ex vivo culture, with minimal impact
on the clinical pathway.
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